The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics introduces ALLO-329, an investigational allogeneic CAR-T therapy intended to transform autoimmune disease treatment.
Powered by the company’s Dagger technology, ALLO-329 aims to reduce or eliminate the need for lymphodepletion, a process that typically precedes cell therapies. This innovation could improve patient experience and broaden access to CAR-T solutions for autoimmune indications. Full clinical data and timeline for regulatory review have not been detailed.
View post on X Loading...
Allogene previously released interim data from its ALPHA3 trial on allogeneic CAR-T therapy for LBCL treatment, highlighting early results in lymphoma patients (see article). The company has also presented new findings on dual CAR-T cells for patients with high-risk multiple myeloma following BCMA therapy (see details). These studies reflect ongoing efforts to expand allogeneic cell therapy options in challenging disease areas.